Zhenyu Gong

Zhenyu Gong

Auto-generated profile, based on publicly available information

Zhenyu Gong

Department of Neurosurgery, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, PR China; Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich, Munich, 81675, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Biomaterials
Verified
Journal Article
Closed access
ZGZhenyu Gong
Zhenyu Gong
DZDairan Zhou
Dairan Zhou
DWDejun Wu
Dejun Wu
YHYaguang Han
Yaguang Han
HYHao Yu
Hao Yu
TXTao Xu
Tao Xu

17 July 2024 in Scientific Data
Verified
Journal Article
Open access
PDF file
ZGZhenyu Gong
Zhenyu Gong
TXTao Xu
Tao Xu
NPNan Peng
Nan Peng
XCXing Cheng
Xing Cheng
CNChen Niu
Chen Niu
HLHongwei Bran Li
Hongwei Bran Li
Brain metastases (BMs) and high-grade gliomas (HGGs) are the most common and aggressive types of malignant brain tumors in adults, with often poor prognosis and short survival. As their clinical symptoms and image appearances on conventional magnetic resonance imaging (MRI) can be astonishingly similar, their accurate differentiation based solely on clinical and radiological information can be very challenging, particularly for “cancer of unknown primary”, where no systemic malignancy is known or found. Non-invasive multiparametric MRI and radiomics offer the potential to identify these distinct biological properties, aiding in the characterization and differentiation of HGGs and BMs. However, there is a scarcity of publicly available multi-origin brain tumor imaging data for tumor characterization. In this paper, we introduce a multi-center, multi-origin brain tumor MRI (MOTUM) imaging dataset obtained from 67 patients: 29 with high-grade gliomas, 20 with lung metastases, 10 with breast metastases, 2 with gastric metastasis, 4 with ovarian metastasis, and 2 with melanoma metastasis. This dataset includes anonymized DICOM files alongside processed FLAIR, T1-weighted, contrast-enhanced T1-weighted, T2-weighted sequences images, segmentation masks of two tumor regions, and clinical data. Our data-sharing initiative is to support the benchmarking of automated tumor segmentation, multi-modal machine learning, and disease differentiation of multi-origin brain tumors in a multi-center setting.

19 March 2020 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
ZGZhenyu Gong
Zhenyu Gong
FHFan Hong
Fan Hong
HWHongxiang Wang
Hongxiang Wang
XZXu Zhang
Xu Zhang
JCJuxiang Chen
Juxiang Chen
Background: The prognosis of the glioblastoma (GBM) is dismal. This study aims to select an optimal RNA signature for prognostic prediction of GBM patients. Methods: For the training set, the long non-coding RNA (lncRNA) and mRNA expression profiles of 151 patients were downloaded from the TCGA. Differentially expressed mRNAs (DEGs) and lncRNAs (DE-lncRNAs) were identified between good prognosis and bad prognosis patients. Optimal prognostic mRNAs and lncRNAs were selected respectively, by using univariate Cox proportional-hazards (PH) regression model and LASSO Cox-PH model. Subsequently, four prognostic scoring models were built based on expression levels or expression status of the selected prognostic lncRNAs or mRNAs, separately. Each prognostic model was applied to the training set and an independent validation set. Function analysis was used to uncover the biological roles of these prognostic DEGs between different risk groups classified by the mRNA-based signature. Results: We obtained 261 DEGs and 33 DE-lncRNAs between good prognosis and bad prognosis patients. A panel of eight mRNAs and a combination of ten lncRNAs were determined as predictive RNAs by LASSO Cox-PH model. Among the four prognostic scoring models using the eight-mRNA signature or the ten-lncRNA signature, the one based on the expression levels of the eight mRNAs showed the greatest predictive power. The DEGs between different risk groups using the eight prognostic mRNAs were functionally involved in calcium signaling pathway, neuroactive ligand-receptor interaction pathway, and Wnt signaling pathway. Conclusion: The eight-mRNA signature has greater prognostic value than the ten-lncRNA-based signature for GBM patients based on bioinformatics analysis.

15 July 2026 in Nature Health
Verified
Journal Article
Open access
JPJiazhen Pan
Jiazhen Pan
BJBailiang Jian
Bailiang Jian
PHPaul Hager
Paul Hager
YZYundi Zhang
Yundi Zhang
CLChe Liu
Che Liu
DRDaniel Rueckert
Daniel Rueckert
Large language models (LLMs) are increasingly used to answer health-related questions and support healthcare workflows, yet evidence for their safety still relies heavily on static benchmarks that can rapidly become obsolete or be optimized against. Here we introduce a Dynamic, Automatic and Systematic (DAS) red-teaming audit framework that continuously stress-tests LLMs for health across four safety-critical axes: robustness, privacy, bias and hallucination. Validated against board-certified clinicians, a suite of adversarial agents autonomously mutates health-related test cases to uncover vulnerabilities in real time. Applying DAS to 15 state-of-the-art LLMs revealed a profound gap between high static benchmark performance and low dynamic reliability—the ‘benchmarking gap’. Despite median MedQA accuracy exceeding 80%, 94% of previously correct answers failed under dynamic robustness testing. This brittleness generalized to the realistic, open-ended HealthBench dataset, where top-tier models exhibited failure rates exceeding 70%, suggesting that high scores on established static benchmarks may reflect superficial memorization. We observed similarly high failure rates across other domains: privacy leaks were elicited in 86% of scenarios, cognitive bias priming altered recommendations in 81% of fairness tests and hallucination rates exceeded 74% in widely used models. By converting LLM safety evaluation for health from a static checklist into a living adversarial audit, DAS provides a scalable framework for surfacing latent risks before such systems are deployed in consumer-facing health assistants and broader clinical workflows.

30 December 2020 in arXiv
Verified
Preprint
Open access
PDF file
Yong-Tao ZhangYong-Tao Zhang
Yong-Tao Zhang
HZHongshen Zhang
Hongshen Zhang
MWMincheng Wu
Mincheng Wu
Shibo HeShibo He
Shibo He
Yi FangYi Fang
Yi Fang
H. Eugene StanleyH. Eugene Stanley
H. Eugene Stanley
Currently, the global situation of COVID-19 is aggravating, pressingly calling for efficient control and prevention measures. Understanding spreading pattern of COVID-19 has been widely recognized as a vital step for implementing non-pharmaceutical measures. Previous studies investigated such an issue in large-scale (e.g., inter-country or inter-state) scenarios while urban spreading pattern still remains an open issue. Here, we fill this gap by leveraging the trajectory data of 197,808 smartphone users (including 17,808 anonymous confirmed cases) in 9 cities in China. We find a universal spreading pattern in all cities: the spatial distribution of confirmed cases follows a power-law-like model and the spreading centroid is time-invariant. Moreover, we reveal that human mobility in a city drives the spatialtemporal spreading process: long average travelling distance results in a high growth rate of spreading radius and wide spatial diffusion of confirmed cases. With such insight, we adopt Kendall model to simulate urban spreading of COVID-19 that can well fit the real spreading process. Our results unveil the underlying mechanism behind the spatial-temporal urban evolution of COVID-19, and can be used to evaluate the performance of mobility restriction policies implemented by many governments and to estimate the evolving spreading situation of COVID-19.